welcome
The Motley Fool

The Motley Fool

Health

Health

AbbVie makes a move into the weight loss market, but it's still a long shot

The Motley Fool
Summary
Nutrition label

63% Informative

The company entered into an agreement with Gubra A/S , a Danish drugmaker, to develop GUB014295 , a potential weight loss therapy.

It's still a long shot Can AbbVie become a leader in the weight loss market? It's too early to say. Being first to market matters, but so does having the most effective medicine.

Despite losing patent exclusivity for Humira two years ago , the company's financial results remain strong.

Stock Advisor’s total average return is 821% — a market-crushing outperformance compared to 167% for the S&P 500.

Don’t miss out on the latest top 10 list, available when you join Stock Advisor on the market.

VR Score

57

Informative language

58

Neutral language

17

Article tone

formal

Language

English

Language complexity

41

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

detected

Known propaganda techniques

not detected

Time-value

medium-lived

Source diversity

1

Affiliate links

no affiliate links